Free Delivery Over $100
|
|
|||
|
||||
OverviewIn a groundbreaking development, a beacon of hope emerges for those battling pancreatic cancer. Following a decade-long hiatus, the FDA has granted approval to a revolutionary drug regimen, heralding a new dawn in the fight against metastatic pancreatic adenocarcinoma (mPDAC). Onivyde, an injectable medication crafted by Ipsen, takes center stage, offering a lifeline alongside oxaliplatin, fluorouracil, and leucovorin. As patients grapple with an aggressive adversary boasting a mere eight to eleven-month life expectancy, this milestone stands as a testament to resilience and progress. Backed by a rigorous trial encompassing 770 chemotherapy-na�ve individuals, the regimen showcased unprecedented efficacy, elevating survival rates and response rates to unprecedented heights. Amidst the backdrop of adversity, this approval not only marks a triumph over disease but also signifies a beacon of hope for countless individuals embarking on the arduous journey towards healing. Full Product DetailsAuthor: Kelly-Gideons PressPublisher: Independently Published Imprint: Independently Published Dimensions: Width: 14.00cm , Height: 0.30cm , Length: 21.60cm Weight: 0.068kg ISBN: 9798321891247Pages: 48 Publication Date: 04 April 2024 Audience: General/trade , General Format: Paperback Publisher's Status: Active Availability: In Print  This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of ContentsReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |
||||
